Synapse - Works

Results (4640)

A phase I trial of intraperitoneal (IP) mesothelin (MSLN)-targeted CAR T-cell therapy in patients with MSLN-positive esophagogastric cancer (EGC) with peritoneal carcinomatosis

Meeting Abstract

Choo, J.; Saini, J.; Gonzalez-Aguirre, A.; Dahi, P.; Hieronymi, S.; Fernstedt, S.; Tan, K. S.; Adusumilli, P. S.; Ku, G. Y.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur)

Meeting Abstract

Romesser, P. B.; Miller, E. D.; Shi, Q.; Dixon, J. G.; Gholami, S.; White, S. B.; Wu, C.; Goulet, C. C.; Jee, K. W.; Wright, C. L.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors

Meeting Abstract

Papadopoulos, K. P.; Cecchini, M.; Khushman, M. M.; Pelster, M.; Rodon Ahnert, J.; Kummar, S.; Yaeger, R.; Sharma, S.; Wells, A. L.; Garofalo, A.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

KEYMAKER-U06: Phase 1/2 umbrella platform study of TROP2 antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab plus chemotherapy (substudy 06C) and sacituzumab tirumotecan plus paclitaxel (substudy 06D) in gastroesophageal adenocarcinoma

Meeting Abstract

Oh, D. Y.; Xu, J.; Tabernero, J.; Van Cutsem, E.; He, T.; Bhaumik, S.; Bhagia, P.; Janjigian, Y. Y.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Preclinical and phase 1/2 data of the CHK1 inhibitor BBI-355 in development for esophageal and gastric cancers (EGC) with EGFR or FGFR2 amplifications

Meeting Abstract

Maron, S. B.; Sharma, M. R.; Spira, A. I.; Rodriguez Rivera, I. I.; Chawla, S. P.; Philipovskiy, A.; Johnson, M. L.; Falchook, G. S.; Wainberg, Z. A.; Hansen, R.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma

Meeting Abstract

Shitara, K.; Enzinger, P. C.; Mohapatra, A.; Janjigian, Y. Y.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC)

Meeting Abstract

Janjigian, Y. Y.; Shitara, K.; Elimova, E.; Zhang, J.; Chen, M. H.; Smyth, E. C.; Lee, J.; Miao, R.; Liu, S.; Holmblad, M.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study

Meeting Abstract

Segal, N. H.; Passhak, M.; Köse, F.; Kubala, E.; Elez, E.; Kawakami, H.; Guren, M. G.; Jonker, D. J.; Xu, R. H.; Riera, J.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (alliance)/SWOG 80702

Meeting Abstract

Nowak, J. A.; Shi, Q.; Twombly, T.; Pederson, L. D.; Ma, C.; Väyrynen, J. P.; Zhao, M. M.; Takashima, Y.; Shergill, A.; Kumar, P.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Genomic analysis of paired primary and metastatic pancreatic ductal adenocarcinoma tumors

Meeting Abstract

McIntyre, C. A.; Rudneva, V.; Richards, A. L.; Park, W.; Jarnagin, W. R.; Donoghue, M.; O'Reilly, E. M.
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save